Skip to main content

Table 3 Univariate analysis of biochemical progression-free survival

From: The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy

Parameter

8-year bPFS [%]

(95%CI)

 p 

PSA

 

0.41

 ≤ 15 ng/ml

66.6

(44.3–88.9)

 

 >15 ng/ml

75.1

(64.9–85.3)

 

ADT

 

0.22

 no

  
 

66.7

(51.2–82.2)

 

 yes

78.4

 
 

(67.0–89.8)

 

Dose (prostate)

 

0.78

 ≤ 74 Gy

76.7

(64.9–88.5)

 

 >74 Gy

68.8

(53.5–84.1)

 

Gleason

 

0.50

 < 7

75.4

(63.4–75.4)

 

 ≥ 7

72.0

(56.9–87.1)

 

Risk category

 

0.58

 Intermediate-risk

76.4

(63.3–89.5)

 

 High-risk

70.9

(57.8–84.0)

 

Age

 

0.13

 ≤ 61 years

70.1

 
 

(59.7–80.5)

 

 > 61 years

88.9

 
 

(68.3–100.0)

 

HIF1α

 

0.019

 ≤ 50%

64.6

(43.0–86.2)

 

 >50%

75.5

(65.1–85.9)

 

EGFR

 

0.05

 strong

61.6

(41.8–81.4)

 

 weak

65.1

(48.0–82.2)

 

 negative

85.0

(71.9–98.1)

 

VEGF-A

 

0.92

l ow

70.5

(51.7–89.3)

 

 high

74.4

(63.6–85.2)

 
  1. PSA prostatic-specific antigen, ADT anti-androgen deprivation therapy.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us